SCHEMBL6072090

SCHEMBL6072090

N#Cc1c(N)nc2ccccc2c1-c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.56
ADORA1 P30542 4/20 0.56
KDM4E B2RXH2 12/20 0.53
ALDH1A1 P00352 5/20 0.53
HSD17B10 Q99714 4/20 0.53
MAPT P10636 3/20 0.53
HPGD P15428 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TSHR P16473 1/20 0.53
HTT P42858 2/20 0.50
ADRA2A P08913 1/20 0.50
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP3A4 P08684 1/20 0.48
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4436700 0.90 ADORA2A (0.60) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL6222369 0.87 ADORA2A (0.57) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL6222930 0.86 ADORA2A (0.57) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL6072774 0.80 ALDH1A1 (0.54) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL6071938 0.80 KDM4E (0.50) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL6779108 0.79 ADORA2A (0.50) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL753198 0.79 PRKAA2 (0.64) ADORA2AADORA1KDM4EALDH1A1SMN1; SMN2
SCHEMBL28746020 0.78 RXFP1 (0.67) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL3357889 0.78 KDM4E (0.57) ADORA2AADORA1KDM4EALDH1A1HSD17B10
SCHEMBL6072087 0.77 ADORA1 (0.65) ADORA2AADORA1KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 ADORA2A 2729/4885ADORA1 2355/4885KDM4E 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.